Antidepressants and ocular health: Addressing dry eye syndrome

Ayesha Mansoor; Sahfaq Mansoor; Amjad Hayat Khan

doi:10.32593/jstmu/Vol7.Iss1.249

Ayesha Mansoor Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan
Sahfaq Mansoor Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan
Amjad Hayat Khan Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan

DOI: https://doi.org/10.32593/jstmu/Vol7.Iss1.249

Keywords: Dry eyes syndrome, kerato-conjunctivitis sicca, antidepressants, serotonin, SSRIs, TCAs

Abstract

Dry eye syndrome (DES) is a common and multifactorial eye disease that can lead to visual disturbance if left untreated. DES arises from various factors such as reduced tear production and inflammation, affects the quality of vision, and can potentially lead to other eye diseases such as pterygium, pseudo pterygium, conjunctivitis, keratitis, corneal ulcers, and corneal dystrophy. Notably, there is an intriguing link between DES and depression, a commonly diagnosed psychiatric disorder characterized by decreased levels of neurotransmitters such as serotonin, dopamine, and norepinephrine. Antidepressants prescribed to treat depression work by increasing serotonin levels but paradoxically can lead to DES and other ocular side effects. In particular, selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are known to contribute to DES development. This article unveils the factors that trigger DES and sheds light on the interconnected casual web. By explaining the intricacies of DES, this article aims to provide physicians and patients with a deeper understanding of the condition, enabling better management and treatment outcomes.

Downloads

Download data is not yet available.

Author Biographies

Ayesha Mansoor, Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan

Student Optometry

Sahfaq Mansoor, Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan

Student Optometry

Amjad Hayat Khan, Department of Allied Health Sciences, Bashir Institute of Health Sciences Islamabad, Pakistan

Assistant Professor

References

Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. Tfos dews ii epidemiology report. Ocular surface. 2017; 15(3):334-65.

DOI: https://doi.org/10.1016/j.jtos.2017.05.003

Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocular surface. 2017; 15(4):802-12.

DOI: https://doi.org/10.1016/j.jtos.2017.08.003

Jerkins GW, Pattar GR, Kannarr SR. A review of topical cyclosporine a formulation—a disease-modifying agent for keratoconjunctivitis Sicca. Clin Ophthalmol (Auckland, NZ). 2020; 14:481.

DOI: https://doi.org/10.2147/OPTH.S228070.

Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocular surface. 2017; 15(1):65-76.

DOI: https://doi.org/10.1016/j.jtos.2016.09.003

Kitazawa M, Sakamoto C, Yoshimura M, Kawashima M, Inoue S, Mimura M, et al. The relationship of dry eye disease with depression and anxiety: a naturalistic observational study. Transl vis sci technol. 2018; 7(6):35.

DOI: https://doi.org/10.1167/tvst.7.6.35

Gonzales JA, Shiboski SC, Bunya VY, Akpek EK, Rose-Nussbaumer J, Seitzman GD, et al. Ocular clinical signs and diagnostic tests most compatible with keratoconjunctivitis sicca: a latent class approach. Cornea. 2020; 39(8):1013.

DOI: https://doi.org/10.1097/ICO.0000000000002311.

Benelli U, Nardi M, Posarelli C, Albert TG. Tear osmolarity measurement using the TearLab™ Osmolarity System in the assessment of dry eye treatment effectiveness. Cont Lens Anterior Eye. 2010; 33(2):61-7.

DOI: https://doi.org/10.1016/j.clae.2010.01.003

Bunya VY, Fernandez KB, Ying G-S, Massaro-Giordano M, Macchi I, Sulewski ME, et al. A Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren's Syndrome. Eye Cont Len. 2018; 44(Suppl 2):S196.

DOI: https://doi.org/10.1097/ICL.0000000000000448.

Bunya VY, Fuerst NM, Pistilli M, McCabe BE, Salvo R, Macchi I, et al. Variability of tear osmolarity in patients with dry eye. JAMA Ophthalmol. 2015; 133(6):662-7.

DOI: https://doi.org/10.1001/jamaophthalmol.2015.0429.

Bunya VY, Langelier N, Chen S, Pistilli M, Vivino FB, Massaro-Giordano G. Tear osmolarity in Sjogren’s syndrome. Cornea. 2013; 32(7):922.

DOI: https://doi.org/10.1097/ICO.0b013e31827e2a5e.

Pepose JS, Sullivan BD, Foulks GN, Lemp MA. The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and clinical trials. Am J Ophthalmol. 2014;57(1):4-6. e1.

DOI: https://doi.org/10.1016/j.ajo.2013.10.020.

Rabbets W. Why is your eye dry? S A Pharmacist Assistant. 2023; 23(2):22-4.

Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. Tfos dews ii pathophysiology report. Ocular Surface. 2017; 15(3):438-510.

DOI: https://doi.org/10.1016/j.jtos.2017.05.011

Abidi A, Shukla P, Ahmad A. Lifitegrast: a novel drug for the treatment of dry eye disease. J Pharmacol Pharmacother. 2016; 7(4):194-8.

DOI: https://doi.org/10.4103/0976-500X.195920.

Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II definition and classification report. Ocular Surface. 2017; 15(3):276-83.

DOI: https://doi.org/10.1016/j.jtos.2017.05.008

Liyue H, Chiang PP-C, Sung SC, Tong L. Dry eye-related visual blurring and irritative symptoms and their association with depression and anxiety in eye clinic patients. Curr Eye Res. 2016; 41(5):590-9.

DOI: https://doi.org/10.3109/02713683.2015.1056804

Hallak JA, Tibrewal S, Jain S. Depressive symptoms in dry eye disease patients: a case-control study using the Beck Depression Inventory. Cornea. 2015; 34(12):1545.

DOI: https://doi.org/10.1097/ICO.0000000000000641.

Na K-S, Han K, Park Y-G, Na C, Joo C-K. Depression, stress, quality of life, and dry eye disease in Korean women: a population-based study. Cornea. 2015; 34(7):733-8.

DOI: https://doi.org/10.1097/ICO.0000000000000464.

Yilmaz U, Gokler ME, Unsal A. Dry eye disease and depression-anxiety-stress: A hospital-based case-control study in Turkey. Pakistan journal of medical sciences. 2015; 31(3):626.

DOI: https://doi.org/10.12669/pjms.313.7091.

Wen W, Wu Y, Chen Y, Gong L, Li M, Chen X, et al. Dry eye disease in patients with depressive and anxiety disorders in Shanghai. Cornea. 2012; 31(6):686-92.

DOI: https://doi.org/10.1097/ICO.0b013e3182261590.

Park C, Rosenblat JD, Brietzke E, Pan Z, Lee Y, Cao B, et al. Stress, epigenetics, and depression: a systematic review. Neurosci Biobehav Rev. 2019; 102:139-52.

DOI: https://doi.org/10.1016/j.neubiorev.2019.04.010.

Yang L, Zhao Y, Wang Y, Liu L, Zhang X, Li B, et al. The effects of psychological stress on depression. Curr Neuropharmacol. 2015; 13(4):494-504.

DOI: https://doi.org/10.2174/1570159x1304150831150507.

Narayanan V. Ocular Adverse effects of antidepressants–need for an ophthalmic screening and follow-up protocol. Ophthalmol Res. 2019; 10(3):1-6.

DOI: https://doi.org/10.9734/or/2019/v10i330107

Huider F, Milaneschi Y, Van der Zee MD, De Geus EJ, Helmer Q, Penninx BW, et al. Major depressive disorder and lifestyle: correlated genetic effects in extended twin pedigrees. Genes. 2021; 12(10):1509.

DOI: https://doi.org/10.3390/genes12101509.

Maguire MJ, Marson AG, Nevitt SJ. Antidepressants for people with epilepsy and depression. Cochrane Database of Systematic Reviews. 2021(4).

DOI: https://doi.org/10.1002/14651858.CD010682.pub3.

De Oliveira CL, Bolzan JA, Surget A, Belzung C. Do antidepressants promote neurogenesis in adult hippocampus? A systematic review and meta-analysis on naive rodents. Pharmacol. Ther. 2020; 210:107515.

DOI: https://doi.org/10.1016/j.pharmthera.2020.107515.

Kohl C, Wang X-D, Grosse J, Fournier C, Harbich D, Westerholz S, et al. Hippocampal neuroligin-2 links early-life stress with impaired social recognition and increased aggression in adult mice. Psychoneuroendocrinology. 2015; 55:128-43.

DOI: https://doi.org/10.1016/j.psyneuen.2015.02.016.

Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiat. 2010; 9(3):155.

DOI: https://doi.org/10.1002/j.2051-5545.2010.tb00298.x.

Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues in clinical neuroscience. 2022.

DOI: https://doi.org/10.31887/DCNS.2008.10.4/gracagni.

Brett J, Karanges EA, Daniels B, Buckley NA, Schneider C, Nassir A, et al. Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry. 2017; 51(10):990-9.

DOI: https://doi.org/10.1177/0004867417721018.

Malhi GS. The right services, at the right time, for the right people. The Lancet Psychiatry. 2019; 6(10):800-2.

DOI: https://doi.org/10.1016/S2215-0366(19)30187-7.

Mondal AC, Fatima M. Direct and indirect evidence of BDNF and NGF as key modulators in depression: role of antidepressants treatment. Int J Neurosci. 2019; 129(3):283-96.

DOI: https://doi.org/10.1080/00207454.2018.1527328.

Rief W, Nestoriuc Y, von Lilienfeld-Toal A, Dogan I, Schreiber F, Hofmann SG, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials. Drug Saf. 2009; 32(11):1041-56.

DOI: https://doi.org/10.2165/11316580-000000000-00000.

Richa S, Yazbek J-C. Ocular adverse effects of common psychotropic agents. CNS Drug. 2010; 24(6):501-26.

DOI: https://doi.org/10.2165/11533180-000000000-00000.

Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: Insights from human and rodent studies. Neuroscience. 2016; 321:138-62.

DOI: https://doi.org/10.1016/j.neuroscience.2015.05.053.

Caviedes A, Lafourcade C, Soto C, Wyneken U. BDNF/NF-κB signaling in the neurobiology of depression. Curr Pharm Des. 2017; 23(21):3154-63.

DOI: https://doi.org/10.2174/1381612823666170111141915.

Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, et al. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep. 2020; 47(1):753-70.

DOI: https://doi.org/10.1007/s11033-019-05129-3.

Lochmann D, Richardson T. Selective serotonin reuptake inhibitors. Antidepressants: Springer; 2018. p. 135-44.

Sabella D. Antidepressant medications. Am J Nurs. 2018; 118(9):52-9.

DOI: https://doi.org/10.1097/01.NAJ.0000544978.56301.f6.

Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depression Anxiety. 2019; 36(3):198-212.

DOI: https://doi.org/10.1002/da.22854.

Ghaffariyeh A, Chamacham T. Tricyclic Antidepressants: Potential Therapeutic Alternatives for Treatment of Dry Eye Symptoms After LASIK. J Refract Surg. 2008; 24(8):770-2.

DOI: https://doi.org/10.3928/1081597X-20081001-01

Sönmez İ, Aykan Ü. Psychotropic drugs and ocular side effects. Turk J Ophthalmol. 2013; 43:270-7.

Mullins N, Lewis CM. Genetics of depression: progress at last. Curr Psychiatry Rep. 2017; 19(8):1-7.

DOI: https://doi.org/10.1007/s11920-017-0803-9

Wu T, Jia X, Shi H, Niu J, Yin X, Xie J, et al. Prevalence of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis. J Affect Disord. 2021; 281:91-8.

DOI: https://doi.org/10.1016/j.jad.2020.11.117.

Acan D, Kurtgoz P. Influence of selective serotonin reuptake inhibitors on ocular surface. Clin Exp Optom. 2017; 100(1):83-6.

DOI: https://doi.org/10.1111/cxo.12415. Epub 2016 Jul 31.

Zhang L, Yu F, Hu Q, Qiao Y, Xuan R, Ji G, et al. Effects of SSRI Antidepressants on Attentional Bias toward Emotional Scenes in First-Episode Depressive Patients: Evidence from an Eye-Tracking Study. Psychiatry Invest. 2020; 17(9):871-9.

DOI: https://doi.org/10.30773/pi.2019.0345.

Isik-Ulusoy S, Ulusoy MO. Influence of different antidepressants on ocular surface in patients with major depressive disorder. J Clin Psychopharmacol. 2021; 41(1):49-52.

DOI: https://doi.org/10.1097/JCP.0000000000001325.

Koçer E, Koçer A, Özsütçü M, Dursun AE, Kirpinar I. Dry eye related to commonly used new antidepressants. J Clin Psychopharmacol. 2015; 35(4):411-3.

DOI: https://doi.org/10.1097/JCP.0000000000000356.

Arenas Rojas ÁV, Torrado Val E, Garrido Fernández M. Intervención familiar en diagnóstico reciente e inicio de tratamiento del cáncer infantil. Apuntes de Psicologia. 2016; 34(2-3):211-220.

Pierre JM. Abuse of psychiatric medications: not just stimulants and benzodiazepines. Curr Psychiatr. 2019; 18(1):11.

Ciobanu AM, Dionisie V, Neagu C, Bolog OM, Riga S, Popa-Velea O. Psychopharmacological treatment, intraocular pressure and the risk of glaucoma: a review of literature. J Clin Med. 2021; 10(13):2947.

DOI: https://doi.org/10.3390/jcm10132947

Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G. Antioxidants as antidepressants. CNS Drug. 2012; 26(6):477-90.

DOI: https://doi.org/10.2165/11633190-000000000-00000.

Van Der Vaart R, Weaver MA, Lefebvre C, Davis RM. The association between dry eye disease and depression and anxiety in a large population-based study. Am J Ophthalmol. 2015; 159(3):470-4.

DOI: https://doi.org/10.1016/j.ajo.2014.11.028.

Szakáts I, Sebestyén M, Németh J, Birkás E, Purebl G. The role of health anxiety and depressive symptoms in dry eye disease. Curr Eye Res. 2016; 41(8):1044-9.

DOI: https://doi.org/10.3109/02713683.2015.1088955

Li M, Gong L, Chapin WJ, Zhu M. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012; 53(9):5722-7.

DOI: https://doi.org/10.1167/iovs.11-9094

Kang H-J, Kim S-Y, Bae K-Y, Kim S-W, Shin I-S, Yoon J-S, et al. Comorbidity of depression with physical disorders: research and clinical implications. Chonnam Med J. 2015; 51(1):8-18.

DOI: https://doi.org/10.4068/cmj.2015.51.1.8

Alderson SL, Foy R, Glidewell L, McLintock K, House A. How patients understand depression associated with chronic physical disease–a systematic review. BMC Fam Pract. 2012; 13(1):1-19.

DOI: https://doi.org/10.1186/1471-2296-13-41

Chhadva P, Lee T, Sarantopoulos CD, Hackam AS, McClellan AL, Felix ER, et al. Human tear serotonin levels correlate with symptoms and signs of dry eye. Ophthalmol. 2015; 122(8):1675.